Frontiers in Oncology (Jul 2014)

A case of retinal tear associated with use of sorafenib

  • Kelly M. Gaertner,
  • Stephen H. Caldwell,
  • Osama eRahma

DOI
https://doi.org/10.3389/fonc.2014.00196
Journal volume & issue
Vol. 4

Abstract

Read online

Inhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related case of ophthalmologic toxicity has been reported with another vascular endothelial growth factor receptor inhibitor, sunitinib. We report the first case of retinal tear possibly associated with sorafenib.

Keywords